Literature DB >> 28515567

Asymmetric, Tender Gynecomastia Induced by Olanzapine in a Young Male.

Mohit Kumar Shahi1, Sujita Kumar Kar1, Amit Singh1.   

Abstract

Entities:  

Year:  2017        PMID: 28515567      PMCID: PMC5385759          DOI: 10.4103/0253-7176.203118

Source DB:  PubMed          Journal:  Indian J Psychol Med        ISSN: 0253-7176


× No keyword cloud information.
Sir, Approximately 10–25% of the causes of gynecomastia are drug-induced.[1] Gynecomastia may result from imbalance in levels of androgen and estrogen as well as the elevated level of prolactin.[2] Drugs involving these hormone systems are likely to cause gynecomastia. Antipsychotic medications-induced hyperprolactinemia may manifest as gynecomastia.[3] Antipsychotic medications such as clozapine, olanzapine, aripiprazole, ziprasidone, and quetiapine possess prolactin-sparing property, hence the risk of gynecomastia with these medications is low.[345] The evidence for olanzapine-induced gynecomastia are scarce and limited to case reports. A 20-year-old male had complaints of suspiciousness, fearfulness, increased physical activity, and decreased sleep for the last 1 week. These symptoms caused significant impairment in day to day functioning. This was the first episode of psychiatric illness. Physical examination of the patient did not reveal any abnormality. His routine blood investigations, thyroid function tests were within normal limits. He was diagnosed with acute and transient psychotic disorder and was started on olanzapine 10 mg/day and clonazepam 0.5 mg/day. The patient had shown improvement on the above treatment and his symptoms resolved completely in a month time. At 6 months follow-up visit, the patient reported painful enlargement of both breasts. The enlargement was asymmetrical; more in the left side than right. The patient did not report any other side effects commonly observed with olanzapine. The dose of olanzapine was reduced to 5 mg/day as the patient was clinical stable and acetaminophen 500 mg was prescribed for pain on as and when required. After 2 months of dose reduction, there was a significant improvement. The tenderness as well as enlargement of both breasts resolved completely. Causality assessment had been done using Naranjo adverse drug reaction probability scale which was suggestive of “probable adverse drug reaction” to olanzapine. Our patient had reported asymmetric, tender enlargement of the breasts (gynecomastia was more evident in left side than right). However, there was no sexual dysfunction. The side effect was reported with 10 mg/day olanzapine which improved when the dose of medication was reduced to 5 mg/day. There is evidence of unilateral gynecomastia with antipsychotic risperidone in a case study by Mendhekar and Andrade;[6] however, similar evidence are lacking for olanzapine. Some evidence also suggest that switching to olanzapine from risperidone improves the treatment-emergent prolactin disturbance and the improvement remains sustained over time.[7] Dopamine and prolactin have antagonistic action with each other. Antipsychotic medications elevate prolactin levels through dopamine blockade. Dopamine blockade is also responsible for the efficacy of antipsychotic medications. It is required to observe whether side effects associated with hyperprolactinemia could predict the response to antipsychotics.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  7 in total

Review 1.  Drug-inducing gynaecomastia--a critical review.

Authors:  W Krause
Journal:  Andrologia       Date:  2011-11-01       Impact factor: 2.775

Review 2.  [Hyperprolactinemia in mentally ill patients].

Authors:  Manuel Maria de Carvalho; Carlos Góis
Journal:  Acta Med Port       Date:  2012-02-20

Review 3.  Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.

Authors:  Peter M Haddad; Angelika Wieck
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine.

Authors:  Bruce J Kinon; Jonna Ahl; Hong Liu-Seifert; Gerald A Maguire
Journal:  Psychoneuroendocrinology       Date:  2006-02-20       Impact factor: 4.905

Review 5.  [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].

Authors:  I Besnard; V Auclair; G Callery; C Gabriel-Bordenave; C Roberge
Journal:  Encephale       Date:  2013-08-05       Impact factor: 1.291

Review 6.  Drug-induced gynecomastia: an evidence-based review.

Authors:  Fnu Deepinder; Glenn D Braunstein
Journal:  Expert Opin Drug Saf       Date:  2012-08-06       Impact factor: 4.250

7.  Unilateral gynecomastia induced by risperidone in a geriatric male patient.

Authors:  D N Mendhekar; C R Andrade
Journal:  Indian J Med Sci       Date:  2005-08
  7 in total
  1 in total

1.  Hyperprolactinemia in Adults Treated With Anti-psychotic Drugs Attending Tertiary Hospitals in Oman: An Observational Study.

Authors:  Mohamed S Al Harthi; Thamra S Al Ghafri; Loai Al Wasify; Salma Al Akhzami; Ahmed AlHarthi; Saud Al Harthi; Nasser Al Sibani
Journal:  Cureus       Date:  2022-01-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.